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Abstract
Objective The objective of this study is to evaluate patient
concerns about in vitro fertilization (IVF) errors and electronic
witness systems (EWS) satisfaction.
Design The design of this study is a prospective single-center
cohort study.
Setting The setting of this study was located in the private
IVF center.
Patient(s) Four hundred eight infertile patients attending an
IVF cycle at a GENERA center in Italy were equipped with an
EWS.
Intervention(s) Although generally recognized as a very rare
event in IVF, biological sample mix-up has been reported in
the literature. For this reason, some IVF laboratories have
introduced EWS with the aim to further reduce the risk of
error during biological samples handling. Participating
patients received a questionnaire developed through a Likert
scale ranging from 1 to 6.
Main outcomes measure(s) Patient concerns about sample
mix-up without and with an EWS were assessed.
Result(s) 90.4 % of patients expressed significant concerns
relating to sample mix-up. The EWS reduced these concerns
in 92.1 % of patients, 97.1 % of which were particularly sat-
isfied with the electronic traceability of their gametes and
embryos in the IVF laboratory. 97.1 % of patients felt highly
comfortable with an IVF center equipped with an EWS.
Female patients had a significantly higher appreciation of
the EWS when compared to their male partners (p = 0.029).
A significant mix-up event occurred in an Italian hospital dur-
ing the study and patient’s satisfaction increased significantly
towards the use of the EWS after the event (p = 0.032).
Conclusion(s) EWS, by sensibly reducing the risk for sample
mix-up in IVF cycles, has been proved to be a trusted strategy
from patient’s perspective.
Keywords Embryo labeling . IVFmix-up . Traceability .
Witnessing system . Patient’s perspective
Introduction
The introduction of the electronic witness system (EWS) in
the in vitro fertilization (IVF) clinical practice is a recent in-
novation. Its use is especially prevalent in the UK where it is
mandated by a specific legislation. Although electronic
witnessing has been recommended to improve traceability
and reducing IVF mix-ups [1], only a few centers have imple-
mented the technology to this point all around the world.
Without an EWS, embryologists are exposed to increased
mismatching risks during the manipulation of biological ma-
terial. In fact, since the first known case of an assisted
Capsule EWS is able to contain patient concerns about possible errors in
biological sample manipulation and will increase patient satisfaction
towards the IVF Clinic, especially after of the embryo exchange that
happened at an Italian Hospital in 2013.
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reproductive technology (ART) mix-up in 1987 inManhattan,
USA [2], the accidental use of incorrect gametes or embryos
during ART procedures has been reported in several centers in
different countries [3, 4]. Many of these mix-ups were detect-
ed because couples gave birth to babies of different skin color
to their own or because fertility clinics later informed patients
of the mistake. It is therefore possible that other cases could
have gone unnoticed. In an IVF center, a biological sample
misidentification could potentially be catastrophic for the clin-
ic, clinic staff, and especially patients.
Embryologists could face legal challenges and regulatory
sanctions, while patients would have to cope with the psycho-
logical damage and with the loss of confidence in the IVF
process impacting on future cycles. For instance, in Italy, there
was a recent high-profile mismatching error at a public hospital
in Rome, in which incorrect embryos were transferred between
two couples. After the embryo mix-up, the woman who got
pregnant has decided to continue the pregnancy, while the oth-
er one that was not pregnant has decided to charge the medical
and biological team, reclaiming her rights on the babies.
Critical points during the clinical and laboratory IVF pro-
cedures have been identified where mismatching of gametes
and embryos is most likely to occur: initial gamete collection,
mixing of gametes by either conventional IVF or IVF with
intracytoplasmic sperm injection, gametes or embryos transfer
between tubes or dishes, freezing and thawing of gametes or
embryos, and embryo transfer into a patient [5].
Without an EWS, the main control measure used to reduce
the risk of biological sample mix-up is a human double-
checking approach. However, this mechanism of control has
been shown to be vulnerable to human errors including: check
omission, check incomplete, involuntary automaticity, and
non-contemporaneous checking [6, 7]. For these reasons, sev-
eral alternative options have been developed in order 1 to re-
place the majority of human manual witnessing steps in IVF:
(i) systems based on barcode labels [8], (ii) systems based on
silicon barcodes that are injected directly into eggs or embryos
[9], and (iii) systems based on Radio Frequency Identification
technology (RFID) [10, 11]. The latter has two major advan-
tages: firstly, it prevents embryologists accidentally working on
more than one patient’s eggs or sperm at a time and, secondly,
it marks each course step, preventing embryologists from omit-
ting key tasks in the process. The use of these electronic sys-
tems is rapidly extending to fertility clinics worldwide [10, 12].
IVF Witness is an EWS (Research Instruments, UK) based
on radio frequency identification (RFID) tags to track and re-
cord patients and samples during IVF. Using RFID tags, pa-
tient’s identity is monitored at every stage of the treatment, and
at the same time, the system captures information regarding the
cycle progress and operator actions. The IVF witness system
monitors every instance when gametes or embryos are trans-
ferred from one container to the next and ensures that only one
patient can be worked on at one time. Monitoring is constant,
so an identity check can never be overlooked. Finally, to safe-
guard the beginning and end of the cycle, each patient is pro-
vided with an individual ID card, used in the treatment rooms,
to verify that the identity of the patient matches that of the eggs,
sperm, and embryos. From a technical perspective, the EWS
works with low-level radio waves as for many other sources of
electromagnetic and radio fields that are usually present in an
IVF laboratory. Even though animal and cell lines studies
showed reassuring data, [13–15] it still needs to be fully deter-
mined whether the systematic use of such electronic devices in
the IVF laboratory might interfere somehow with the biology
of gametes and embryos. However, other than using very mod-
erate radio frequencies, the exposition time is limited to only
few seconds that are required during some steps of cells ma-
nipulation outside the incubators. When in the incubator, the
electronic tags are not receiving or emitting radio waves at all.
Furthermore, efforts should still be made to improve the cost-
effectiveness of the EWS devices in order to allowmore clinics
and patients to benefit from its routine application in IVF.
IVFWitness was recently introduced in our IVF laboratory,
and the ID card is given to the patient that keeps it from oocyte
retrieval to embryo transfer. This is the first study investigat-
ing the patient perspective about the implementation of such
technology in the IVF practice. We have designed a prospec-
tive study with the purpose of measuring patient’s awareness
and concerns about a possible mismatch error and their satis-
faction in response to the advantages of this electronic system
and if this solution could reduce their worries about biological
mix-up.
Furthermore, during the course of the study, there was a
high-profile mismatching error at public hospital in Rome,
Italy, in which incorrect embryos were transferred between
two couples. The publication of this catastrophic event by
the Italian mass media enabled us to measure patient prospec-
tive on the EWS before and after becoming aware of the sig-
nificant mismatch event.
Materials and methods
This is a prospective study performed between September
2013 and December 2014 in a single private infertility center
(GENERA Centre for Reproductive Medicine, Rome).
We recruited 408 consecutive infertility patients that were
interviewed 1 on the day of embryo transfer by a psychological
team. All patients were informed about the use of EWS on the
day of oocyte retrieval and were given an individual electronic
ID card by the embryological team. On the day of the embryo
transfer, patients were introduced to the psychologist who gave
them the questionnaire and explained the purpose of the study.
Because of the catastrophic embryo mix-up event that oc-
curred in an Italian hospital during the study period, we were
able to compare two patient groups; one group of patients
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before the event and the other group after the event were made
public. Each group consisted of 204 consecutive patients that
received the same questionnaire. The main socio-
demographic variables considered were the following: age
of partners, gender, and number of previous IVF attempts (in
other or in our reproductive center).
The institutional review board of the Valle Giulia Clinic
approved the study, and signed informed consent was obtain-
ed from all patients recruited.
Questionnaire layout
A patient’s prospective ad hoc questionnaire was devel-
oped with consideration of the possible ambiguities that
the patients could have during an IVF treatment cycle
with respect to the clinic practices and the patients con-
cerns about a potential mismatch occurring in the labora-
tory. The target of the questionnaire was to identify dif-
ferent issues related to patient’s awareness of a possible
biological sample mix-up, their worries about this possi-
bility, the degree of satisfaction towards the use of a new
EWS (IVF Witness; Research instruments, UK) in clinical
IVF procedures, and the satisfaction levels towards clinics
using the technology.
The questionnaire was composed of seven questions, and
each was linked to an answer on a Likert scale of values
ranging from 1 to 6. The values corresponded to either cate-
gorical variables (1=No, never; 2= Rarely; 3= Sometimes;
4=Frequently; 5=Always; 6=No viewpoint) or to a nominal
variable (1=No worries; 2=Lack of information on its use;
3=Loss of your personal electronic card; 4=Because it is an
electronic device; 5=No viewpoint) (Table 1).
Statistical analysis
Data are expressed as absolute counts and percentages and
also as median ± inter-quartile range. Continuous measure-
ments are expressed as mean ± standard deviation or as medi-
an ± inter-quartile range as appropriate. Two sample compari-
sons were based onMann-Whitney rank-sum test or Student’s
t test as appropriate. Relationship between 1 main predictors
and question responses was evaluated by means of polytomic
logistic regressionwith question-specific intercept. In compar-
ing pre- and post alien mix-up event patients, we summarized
two questions via principal component analysis (PCA). PCA
was used to obtain the optimal summary between these two
questions (as opposed to a simple score average which would
have been sub-optimal). The resulting summary was treated as
a continuous variable. All hypothesis tests were two-tailed.
All p values reported are Bonferroni adjusted for multiplicity,
where an adjusted p value <0.05 was considered as statistical-
ly significant.
Results
A total of 408 patients were evaluated: 198 were male
(48.52 %) with an average age of 39.64 years old (SD = 5.4)
and 210 (51.47 %) were female with an average age of 36.39
(SD = 4.0) years old.
The female population was younger compared to males
(p < 0.01). A mean number of 2.2 (SD = 1.8) previous IVF
treatment cycles were performed in our clinic, while the aver-
age number of the attempts performed in other infertility
clinics was 1.2 (SD = 1.7).
Detailed data obtained from the questionnaire per single
question are reported in Tables 2. We observed that 369
(90.43 %) of patients being concerned of an error in the bio-
logical manipulation of samples with varying degree (question
n.1). We also analyzed if the introduction of the EWS would
be able to reduce patient’s concern about a biological mix-up
in IVF. 376/408 (92.15 %) of the patients confirmed that their
concerns would be reduced if the new control device were
available (question n.2). In analyzing the patient’s approval
of the EWS with respect to its ability to mark every step in
the laboratory routine (question 3), we found that 396/408
(97.06 %) patients had some degree of approval.
The use of a sound alarm to alert the operators about an
ongoing risk of mix-up or about procedural mistakes was ap-
preciated by 97.55% of patients interviewed (Table 2 question
4).
Among the possible issues related to the practical use of an
EWS, most patients declared no worries at all (31.86 %,
Table 2 question 5). Few patients expressed some concerns
related to the electronic nature of the device (15.20%), follow-
ed by the lack of information about its use (16.12 %), while
most of them were concerned about the possibility of an oc-
casional loss of the electronic card (29.90 %). Before starting
the IVF treatment, patients received an EW card that was kept
until the day of embryo transfer. The accidental loss of the
card represented a noticeable source of concern. However,
when informed about the possibility to 1 obtain a duplicate
card and that losing the electronic card would not affect the
procedure, they were much more comfortable and felt
reassured (Table 2 question 6).
Finally, we assessed patient satisfaction towards centers
that implemented the EWS (question n.7).
398/408 patients (97.1 %) were more satisfied if an EWS
was used in their treating clinic. It was noted that patient age
and gender was significantly associated with the responses to
question 7 (Table 3). In particular, younger patients were more
likely to prefer a clinic that had implemented an EWS system
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(p = 0.032), and females were significantly more likely (one
point in median on the Likert scale) than men (p = 0.029).
Comparison of patient’s perspective in the pre-
and post mix-up event period
In the next step, we compared patients’ perspective before and
after the mentioned embryo mix-up event that occurred in
another clinic in the same city.
The first group (hereafter defined as pre-event) was made
of 204 patients of which 99 were male (48.52 %) with a mean
age of 39.12 (SD = 4.8) and 105 (51.47) were female, with a
mean age of 36.4 (SD = 5.2). The mean previous IVF attempts
made in our clinic were 2.40 (SD = 1.7), and the mean previ-
ous IVF attempts made in other clinics was 0.60 (SD = 1.2).
The second group (hereafter defined as post-event) also
consisted of 204 patients of which were 99 male (48.52 %)
with a mean age of 40.16 (SD = 6.6) and 105 were female
(51.47 %) with a mean age of 36.39 (SD = 4.1). The mean
previous IVF attempts made in our clinic were 2.02
(SD = 1.9), and the mean previous IVF attempts made in other
clinics was 1.79 (SD = 2.0).
There were no significant differences in gender, age, or
number of IVF attempts at our clinic or in other clinics be-
tween the two groups. We decided to combine the replies to
questions 3 and 7 of the questionnaire to obtain a single mea-
sure of the aptitude towards an EWS, which could also be
sensitive to the advertisement of the mix-up event by the
Table 1 Questionnaire’s
questions to evaluate patient’s
perspective on different features
of electronic witness systems
QUESTION 1
Supposing a mix-up due to human error during the manipulation of your biological
samples occurs, even though the probability is extremely low, of, how much
does it worry you?
1 = Not at all 2 = A little 3 = Moderately 4 = A lot 5 = Extremely 6 = No viewpoint
1 2 3 4 5 6
QUESTION 2
If you were aware of the implementation of a new device (electronic witness) able
to minimize the possibility of human error during IVF procedures, would your
concerns about a sample mix up be reduced?
1 = Not at all 2 = A little 3 = Moderately 4 = A lot 5 = Extremely 6 = No viewpoint
1 2 3 4 5 6
QUESTION 3
The electronic witness (described in Item. 3) is able to track and check every step of
sample manipulation in the IVF laboratory. Therefore, each phase and procedure
performedwith your gametes and embryos is tracked and recorded. In relation to
the sentence above, how much would you appreciate the use of this new device
during your treatment?
1 = Not at all 2 = A little 3 = Moderately 4 = A lot 5 = Extremely 6 = No viewpoint
1 2 3 4 5 6
QUESTION 4
The electronic witness is programmed to go in alarm if there is a sample mix up or
other identifying element or label discrepancy. Given this particular feature of
the instrument, how much would you like to use the device during your
treatment?
1 =Not at all 2 = A little 3 =Moderately 4 =A loth 5 = Extremely 6 =No viewpoint
1 2 3 4 5 6
QUESTION 5
If you were to benefit from the use of the electronic witness during your IVF
treatment, reassured by the extra degree of control, what aspect would bother
you most?
1 = No worries at all 2 = Lack of information on its use 3 = Loss of the personal
electronic card
4 = The fact that it’s an electronic device 5 = No viewpoint
1 2 3 4 5 6
QUESTION 6
Would you feel more at ease in using the electronic witness if you knew in advance
that in case of loss of your personal electronic card there wouldn’t be any
problem because a duplicate is available?
1 = No 2 = Yes, a little 3 = Yes, moderately 4 = Yes, a lot 5 = Yes, extremely 6 = No
viewpoint
1 2 3 4 5 6
QUESTION 7
Now that you are aware of this technological innovation, how much does it
increase your preference and trust in an IVF center that uses it?
1 = Not at all 2 = A little 3 = Moderately 4 = A lot 5 = Extremely 6 = No viewpoint
1 2 3 4 5 6
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Italian media. The summary score was statistically different
between the two groups (p = 0.032), showing an overall in-
crease in attention of patients towards the implementation and
use of an EWS in IVF clinical practice.
Finally, the distribution of scores obtained by comparing
the responses of patients to the questions n. 1 and n. 7 was
observed in a narrow time window around the mix-up event.
In particular, questions 1 and 7 were observed at five different
time points: between 30 and 15 days before (pre T0, N = 32),
15 days before (pre T1, N = 29), in the 15 days following the
mix-up event (mix-up T2; N = 34), between 15 days and
1 month after (post T3, N = 28), and in the following15 days
(post T4; N = 27). As shown in Fig. 1, it was possible to ob-
serve a significant increase (p < 0.01) in the number of patients
showing extreme concerns about the possibility of a human 1
error in the procedures, as well as in patients showing extreme
satisfaction toward an IVF clinic using EWS compared to
patients receiving the interview in the immediate pre-event
period. The effect of the mix-up event last for 1 month fol-
lowing the media reporting and then falls down to moderately
higher levels (Fig. 1).
Discussion
When the EWS was introduced into our IVF setting, the at-
tention was focused on reducing the possible errors, increase
registration, standardization, and traceability, thus making
IVF procedures safer and straightforward in our center. In this
study, we focused on the patient perspective of the clinical
utilization of EWS. We began by considering if patients were
aware of the possibility of a sample mix-up error in the IVF
Table 2 Descriptive analysis of questionnaire’s question inter-quartile range (IQR)
Likert
score
N. Patients
(%)
MEDIAN ± IQR
QUESTION 1:
Biological samples mix-up
1 = Not at all 2 = A little 3 = Moderately 4 = A lot 5 = Extremely 6 = No viewpoint
1.00 36 (8.82) 3 ± 2
2.00 132 (32.35)
3.00 71 (17.40)
4.00 69 (16.91)
5.00 97 (23.77)
6.00 3 (0.63)
QUESTION 2:
Laboratory device to avoid human errors
1 = Not at all 2 = A little 3 = Moderately 4 = A lot 5 = Extremely 6 = No viewpoint
1.00 28 (6.86) 4 ± 2
2.00 60 (14.71)
3.00 74 (18.14)
4.00 125 (30.64)
5.00 117 (28.68)
6.00 4 (0.98)
QUESTION 3:
Satisfaction toward the tracking property of the Electronic Witness
1 = Not at all 2 = A little 3 = Moderately 4 = A lot 5 = Extremely 6 = No viewpoint
1.00 8 (1.96) 5 ± 1
2.00 11 (2.70)
3.00 38 (9.31)
4.00 118 (28.92)
5.00 229 (56.13)
6.00 4 (0.98)
QUESTION 4:
Appreciation of EWS ability to signal in case of sample mix-up
1 = Not at all 2 = A little 3 = Moderately 4 = A lot 5 = Extremely 6 = No viewpoint
1.00 4 (0.98) 5 ± 1
2.00 4 (0.98)
3.00 39 (9.56)
4.00 119 (29.17)
5.00 240 (58.82)
6.00 2 (0.49)
QUESTION 5:
Possible concerns on the use of Electronic Witness
1 = Noworries at all 2 = Lack of information on its use 3 = Loss of the personal electronic card 4 = the fact that it’s
an electronic device 5 = No viewpoint
1.00 130 (31.86) 3 ± 2
2.00 66 (16.18)
3.00 122 (29.90)
4.00 62 (15.20)
5.00 28 (6.86)
QUESTION 6:
Attitude toward EWS card loss
1 = Not at all 2 = A little 3 = Moderately 4 = A lot 5 = Extremely 6 = No viewpoint
1.00 21 (5.15) 4 ± 2
2.00 44 (10.78)
3.00 60 (14.71)
4.00 118 (28.92)
5.00 146 (35.78)
6.00 19 (4.66)
QUESTION 7:
Satisfaction toward the IVF clinic using EWS
1 = Not at all 2 = A little 3 = Moderately 4 = A lot 5 = Extremely 6 = No viewpoint
1.00 2 (0.49) 5 ± 1
2.00 7 (1.72)
3.00 58 (14.22)
4.00 130 (31.86)
5.00 203 (49.75)
6.00
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laboratory and then set out to assess their concerns. We devel-
oped a questionnaire that could evaluate patient’s perspective
on different features of an EWS (Table 1). We investigated if
the EWS reduced patient concerns about identification errors,
how much patients appreciated the new device and if it could
increase patient satisfaction with respect to our IVF clinic
where we used this system.
Through the first phase of the questionnaire, we highlight-
ed how most patients had significant concerns about a biolog-
ical sample mix-up, but only when made aware about it as a
possibility during their treatment. This data suggests that the
idea of a possible errors in the laboratory might represents a
significant source of stress when undergoing IVF, which prop-
erly meets the stress definition as a pattern of negative phys-
iological states and psychological responses occurring in sit-
uations where individuals perceive threats to their well-being,
which they may be unable to meet [16]. It is well known that
IVF can be very stressful for the couples. In general, infertility
and IVF treatment can be considered particularly stressful life
events. According to the model of Lazarus, these events rep-
resent a major life change and involve a sense of frustration,
because what was considered as a natural event lifecycle turns
into a path medicalized by uncertain outcome [17]. Studies
highlighted how the most stressful events of an IVF cycle
are: failure of the treatment, the oocytes retrieval, and most
of all the waiting period between embryo transfer and preg-
nancy test [18–21]. In addition to these aspects, our study
showed that the possibility of an error in the laboratory is an
additional source of stress, as it would be an event beyond the
control of patients and 1 therefore could lead to negative emo-
tional reactions such as frustration, worry, and anxiety.
In this study, we have also established the capacity of an
EWS to reduce the patient concerns relating to identification
errors. We note that the implementation of this new device
was able to reassure patients and alleviate their concerns.
This showed that the EWS is an instrument capable of reduc-
ing stress and represents a protective tool that could be bene-
ficial for patient well-being, especially for those patients that
are more sensitive to developing emotional distress.
When considering the general satisfaction with respect to
the EWS, we note that most patients appreciated the use of the
new control device, and they felt highly comfortable with an
IVF center equipped with EWS. In this context, an EWS can
be seen as a tool to improve patient satisfaction during an IVF
cycle in addition to increasing procedural safety in the
laboratory.
Table 3 Descriptive analysis of questionnaire’s question 4 and 8 for the pre- and post-event groups
PRE - EVENT question 3 and question 7 POST - EVENT question 3 and question 7
QUESTION 3
Satisfaction toward the
tracking property of the
Electronic Witness
1 = Not at all 2 = A little
3 = Moderately 4 = A lot
5 = Extremely 6 = No viewpoint
Frequency (%) Median ± IQR QUESTION 3
Satisfaction toward the
tracking property of the
Electronic Witness
1 = Not at all 2 = A little
3 = Moderately 4 = A lot
5 = Extremely 6 = No viewpoint
Frequency (%) Median ± IQR
1 2 (1.0) 5 ± 1 1 6 (2.9) 5 ± 1
2 5 (2.5) 2 6 (2.9)
3 22 (10.8) 3 16 (7.8)
4 61 (29.9) 4 57 (27.9)
5 113 (55.4) 5 116 (56.9)
6 1 (0.5) 6 3 (1.5)
Total 204 (100.0) Total 204 (100.0)
QUESTION 7
Satisfaction toward the
IVF clinic using EWS
1 = Not at all 2 = A little
3 = Moderately 4 = A lot
5 = Extremely 6 = No viewpoint
Frequency (%) Median ± IQR QUESTION 7
Satisfaction toward
the IVF clinic using EWS
1 = Not at all 2 = A little
3 = Moderately 4 = A lot
5 = Extremely 6 = No viewpoint
Frequency (%) Median ± IQR
1 0 (0) 5 ± 1 1 2 (1.0) 4 ± 1
2 2 (1.0) 2 5 (2.5)
3 28 (13.7) 3 30 (14.7)
4 58 (28.4) 4 72 (35.3)
5 113 (55.4) 5 90 (44.1)
6 3 (1.5) 6 5 (2.5)
Total 204 (100.0) Total 204 (100.0)
IQR inter-quartile range
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Another interesting point that our data showed was that
women had a greater appreciation of the EWS and the
clinic in which it was used when compared to men. This
is compatible with numerous studies that have document-
ed that men and women use different strategies to cope
with IVF treatment. It has been observed that women are
more inclined to talk about IVF difficulties and their emo-
tional burden, while men are more distancing and emo-
tionally self controlling [22]. Women could therefore be
considered to be more inclined to give consideration to
some IVF issues, as in this case. We also note that the
older women in the study tended towards a lower EWS
satisfaction. We hypothesize that they could be less famil-
iar with the technology or due to the lower enthusiasm
related to a lower pregnancy chance.
When we compared the two patient groups (pre- and
post mix-up event), we observed how the satisfaction to-
wards the EWS significantly increased in the post-event
group and how these patients felt significantly more com-
fortable with an IVF center equipped with an EWS. This
high-profile mismatching error that was made public dur-
ing the course of the study is likely to have had an emo-
tional impact on patients who became aware of it, making
these patients more interested in the technical aspects of
IVF procedures and possible risk associated with biolog-
ical sample manipulation.
Moreover, the analysis of patient’s concerns about hu-
man errors in IVF laboratory and on their satisfaction
toward a clinic using EWS performed within a narrow
time intervals close to the mix-up event revealed that the
media influence on patient perspective was particularly
effective in the 15 days after the reporting of the event.
In this period, patients were extremely worried about the
possibility of human error in IVF laboratories and felt
extremely satisfy to perform their treatment in an IVF
clinic using EWS. However, the magnitude of this ex-
treme 1 effect last for about 1 month, with patient feeling
coming back to slightly normal values afterwards. This
observation is consistent with the general impact of mass
media on people view.
In conclusion, our data have highlighted that an EWS is a
valid instrument in an IVF clinic.
Not only it does safeguard all the step of IVF procedures,
decreasing the error risk, but it also has an important role in
IVF patient’s point of view. From a psychological perspec-
tive, an EWS can increase patient well-being during IVF
treatment and can minimize an additional source of stress
that could overload a patient’s emotional balance.
Fig. 1 Descriptive timeline analysis of patients showing extremely high
concerns in the timeframe around the reporting of mix-up event happened
in a public hospital in Rome (a). Descriptive timeline analysis of patients
showing extremely high satisfaction in the timeframe around the
reporting of mix-up event happened in a public hospital (b). Pre T0
between 30 and 15 days before, Pre T1 15 days before, mix-up T3
15 days after the mix-up event was publically reported by the mass
media, Post T3 15 days after, Post T4 between 15 and 30 days after,
EWS electronic witness system
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